The global immune checkpoint inhibitors (ICI) market is set for significant expansion, projected to grow from USD 62.51 billion in 2024 to USD 189.40 billion by 2033, registering a robust CAGR of 11.98% during the forecast period (2025–2033). The surge in cancer prevalence, increasing adoption of immunotherapy, and rapid advancements in precision medicine are key...
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek